Instem : Grants to Directors under the Instem Long Term Incentive Plan (‘LTIP’)

26 February 2018

Instem plc
('Instem' or the 'Company')

Grants to Directors under the Instem Long Term Incentive Plan

Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, announces that Chief Executive Officer, Phil Reason and Chief Financial Officer, Nigel Goldsmith have each been granted nil-cost options over 80,000 Instem ordinary shares of 10p ('Ordinary Shares') under the Company's long-term incentive plan ('LTIP').

These 160,000 share options will become exercisable in 2021, subject to meeting share price targets, pursuant to the rules of the LTIP, which was approved by the Board on 22 February 2018. Following exercise of the options, the resulting shares will then be subject to a minimum 12-month holding period.

After these grants of options, Phil Reason and Nigel Goldsmith hold a total of 384,606 and 217,500 share options, respectively whilst their holdings in Ordinary Shares remain unchanged at 665,287 and Nil, respectively.

For further information, please contact:

Instem plc	www.instem.com
Phil Reason, CEO	[phone]
Nigel Goldsmith, CFO
N+1 Singer (Nominated Adviser & Broker)	[phone]
Richard Lindley
James White
Rachel Hayes
Wallbrook Financial PR	Tel: [phone]
Paul Cornelius	or [e-mail]
Sam Allen
Helen Cresswell

About Instem

Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management and Data Collection; Regulatory Solutions for Submissions and Compliance; and Informatics-based Insight Generation.
Instem solutions are in use by customers worldwide and enable our clients to bring life enhancing products to market faster.
Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

To learn more about Instem solutions and its mission, please visit instem.com.